Replimune will again submit its melanoma drug for approval
Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...
May 29, 2026 11:07 AM EDT FDA+ Replimune to ask FDA for re-review of melanoma drug, as agency stands by past rejections Max Bayer Senior Reporter Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that